Q1 Earnings Estimate for LENZ Issued By Leerink Partnrs

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Leerink Partnrs analyst M. Goodman expects that the company will earn ($0.53) per share for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q2 2025 earnings at ($0.62) EPS and Q4 2025 earnings at ($0.83) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

A number of other analysts have also recently weighed in on LENZ. TD Cowen began coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They set a “buy” rating and a $60.00 price objective for the company. Citigroup increased their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, LENZ Therapeutics has a consensus rating of “Buy” and a consensus target price of $41.67.

LENZ Therapeutics Stock Performance

Shares of LENZ opened at $26.43 on Monday. The company has a 50-day simple moving average of $24.30 and a 200-day simple moving average of $27.12. The firm has a market capitalization of $726.85 million, a P/E ratio of -5.54 and a beta of 0.58. LENZ Therapeutics has a 52 week low of $14.42 and a 52 week high of $38.93.

Institutional Trading of LENZ Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LENZ. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of LENZ Therapeutics in the 4th quarter valued at $29,000. KLP Kapitalforvaltning AS acquired a new position in LENZ Therapeutics in the fourth quarter valued at about $46,000. Tower Research Capital LLC TRC boosted its holdings in LENZ Therapeutics by 162.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock worth $54,000 after buying an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in shares of LENZ Therapeutics during the 4th quarter worth about $67,000. Finally, SG Americas Securities LLC increased its stake in shares of LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after acquiring an additional 935 shares during the last quarter. 54.32% of the stock is owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.